We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

67 hedge funds and large institutions have $33.5M invested in Matinas BioPharma in 2021 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 9 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 9

15% more capital invested

Capital invested by funds: $29.2M → $33.5M (+$4.24M)

0% more funds holding

Funds holding: 67 → 67 (0)

0% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 13

0.13% less ownership

Funds ownership: 0.37% → 0.24% (-0.13%)

Holders
67
Holders Change
–
Holders Change %
0%
% of All Funds
1.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
21
Reduced
9
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SIG
Sargent Investment Group
Maryland
+$907K
2
AWA
Arkadios Wealth Advisors
Georgia
+$905K
3
VF
Virtu Financial
New York
+$199K
4
CCM
Courage Capital Management
Tennessee
+$173K
5
Citadel Advisors
Citadel Advisors
Florida
+$160K

Top Sellers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
-$8.89M
2
GCP
GSA Capital Partners
United Kingdom
-$812K
3
Victory Capital Management
Victory Capital Management
Texas
-$768K
4
Renaissance Technologies
Renaissance Technologies
New York
-$472K
5
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$465K
Name Holding Trade Value Shares
Change 		Change in
Stake
CSS
51
Cubist Systematic Strategies
Connecticut
$16K +$10.9K +252 New
JWCA
52
J.W. Cole Advisors
Florida
$14K – – –
BJL
53
Brighton Jones LLC
Washington
$13K – – –
CFS
54
CRA Financial Services
New Jersey
$13K – – –
FAIM
55
Financial Advocates Investment Management
Washington
$13K – – –
FC
56
Fore Capital
New York
$13K – – –
UBS Group
57
UBS Group
Switzerland
$13K +$6.69K +155 +304%
AAS
58
Avantax Advisory Services
Texas
$13K +$8.63K +200 New
MIFH
59
Migdal Insurance & Financial Holdings
Israel
$12K +$8.07K +187 New
EWM
60
Endurance Wealth Management
Rhode Island
$9K +$5.82K +135 New
SPIA
61
Steward Partners Investment Advisory
New York
$4K – – –
SWM
62
Spire Wealth Management
Virginia
$4K +$2.59K +60 New
HFM
63
Hartford Financial Management
Connecticut
$3K – – –
IA
64
IFP Advisors
Florida
$2K – – –
Bank of America
65
Bank of America
North Carolina
$2K +$1.47K +34 +1,700%
HR
66
Howe & Rusling
New York
$1K -$431 -10 -50%
GWMIA
67
Global Wealth Management Investment Advisory
Florida
$1K – – –
BC
68
Boxer Capital
California
– -$8.89M -229,573 Closed
Renaissance Technologies
69
Renaissance Technologies
New York
– -$472K -12,183 Closed
Hudson Bay Capital Management
70
Hudson Bay Capital Management
Connecticut
– -$465K -12,000 Closed
Two Sigma Advisers
71
Two Sigma Advisers
New York
– -$236K -6,086 Closed
AC
72
AWH Capital
Texas
– -$136K -3,500 Closed
Cerity Partners
73
Cerity Partners
New York
– -$95K -2,460 Closed
Stifel Financial
74
Stifel Financial
Missouri
– -$63K -1,620 Closed
Two Sigma Investments
75
Two Sigma Investments
New York
– -$20K -525 Closed
1 2
3
4

MTNB Hedge Fund Activity: Q3 2021 in Review

67 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q3 2021, worth a combined $33.5M — up 15% from $29.2M a quarter earlier.

Fund positioning in MTNB was balanced in Q3 2021: 13 funds opened new positions, 13 closed out, 21 added to existing stakes and 9 trimmed.

The largest buyer was Sargent Investment Group, adding an estimated $907K. The largest seller was Boxer Capital, exiting entirely with an estimated $8.89M sold.

  • 67 institutional investors held Matinas BioPharma (MTNB) as of Q3 2021, unchanged from Q2 2021.
  • Funds reported $33.5M of Matinas BioPharma stock for Q3 2021, up 15% quarter-over-quarter.
  • 13 funds opened new Matinas BioPharma positions in Q3 2021 and 13 closed out, a net change of 0 holders.
  • The largest Matinas BioPharma buyer in Q3 2021 was Sargent Investment Group, an estimated $907K added.
  • The largest Matinas BioPharma seller in Q3 2021 was Boxer Capital, an estimated $8.89M sold.

Based on aggregated 13F filings for Q3 2021.